Guan Sen Kew1, Mabel Tan2, Toon Wei Lim3. 1. National University Hospital , Singapore , Singapore. 2. Singapore General Hospital , Singapore , Singapore. 3. National University Hospital, Singapore, Singapore; National University Heart Centre, Singapore, Singapore.
Abstract
INTRODUCTION: Atrial fibrillation (AF) is a well-known cause of strokes and all major society guidelines recommend oral anticoagulants (OAC) such as vitamin K antagonists (VKA) for patients with concomitant risk factors to prevent them. However, compliance with these guidelines is historically poor. This study aims to evaluate the adherence to CHADS2 (congestive heart failure, hypertension,age ≥75 years, diabetes mellitus and prior stroke or transient ischaemic attack) guidelines, explore reasons and evaluate outcomes for non-adherence in a tertiary cardiology unit. MATERIALS AND METHODS: A retrospective study of patients admitted into a tertiary cardiology unit from January to March 2010. RESULTS: Of 1826 unique cardiac patients screened, 163 (8.9%) of them had non-valvular AF or atrial flutter. Their mean age was 69.8 years and 58.9% were men. Of the 54 patients on warfarin with documented international normalised ratio (INR), only 22 (40.7%) of them had an INR within the therapeutic range (INR less than two in 22 (40.7%) and greater than three in 10 (18.5%)). Of the 119 patients with CHADS2 greater than or equal to two, only 46 (38.7%) were discharged with warfarin. Among the remaining 73 (61.3%) patients, the most common reasons for not prescribing warfarin include history of bleeding (n=24, 32.9%), no reason documented (n=17, 23.3%) and patient preference (n=12, 19.2%). On follow-up, patients on warfarin were found to have better survival outcomes (mean 1522±41 days) as compared with (mean 1255±63 days) in patients not on OAC (p value=0.001). CONCLUSIONS: Few patients who require anticoagulation receive it in accordance with the guidelines even in a tertiary cardiology unit. There are many impediments to the effective use of VKA for stroke prevention among patients with AF.
INTRODUCTION:Atrial fibrillation (AF) is a well-known cause of strokes and all major society guidelines recommend oral anticoagulants (OAC) such as vitamin K antagonists (VKA) for patients with concomitant risk factors to prevent them. However, compliance with these guidelines is historically poor. This study aims to evaluate the adherence to CHADS2 (congestive heart failure, hypertension,age ≥75 years, diabetes mellitus and prior stroke or transient ischaemic attack) guidelines, explore reasons and evaluate outcomes for non-adherence in a tertiary cardiology unit. MATERIALS AND METHODS: A retrospective study of patients admitted into a tertiary cardiology unit from January to March 2010. RESULTS: Of 1826 unique cardiac patients screened, 163 (8.9%) of them had non-valvular AF or atrial flutter. Their mean age was 69.8 years and 58.9% were men. Of the 54 patients on warfarin with documented international normalised ratio (INR), only 22 (40.7%) of them had an INR within the therapeutic range (INR less than two in 22 (40.7%) and greater than three in 10 (18.5%)). Of the 119 patients with CHADS2 greater than or equal to two, only 46 (38.7%) were discharged with warfarin. Among the remaining 73 (61.3%) patients, the most common reasons for not prescribing warfarin include history of bleeding (n=24, 32.9%), no reason documented (n=17, 23.3%) and patient preference (n=12, 19.2%). On follow-up, patients on warfarin were found to have better survival outcomes (mean 1522±41 days) as compared with (mean 1255±63 days) in patients not on OAC (p value=0.001). CONCLUSIONS: Few patients who require anticoagulation receive it in accordance with the guidelines even in a tertiary cardiology unit. There are many impediments to the effective use of VKA for stroke prevention among patients with AF.
Authors: Daniel E Singer; Robert A Hughes; Daryl R Gress; Mary A Sheehan; Lynn B Oertel; Sue Ward Maraventano; Dyan Ryan Blewett; Bernard Rosner; J Philip Kistler Journal: N Engl J Med Date: 1990-11-29 Impact factor: 91.245
Authors: Lawrence Baruch; Brian F Gage; Jay Horrow; Steen Juul-Möller; Arthur Labovitz; Maria Persson; Miguel Zabalgoitia Journal: Stroke Date: 2007-08-02 Impact factor: 7.914
Authors: Peter J Zimetbaum; Amit Thosani; Hsing-Ting Yu; Yan Xiong; Jay Lin; Prajesh Kothawala; Matthew Emons Journal: Am J Med Date: 2010-05 Impact factor: 4.965
Authors: Carl van Walraven; Robert G Hart; Daniel E Singer; Andreas Laupacis; Stuart Connolly; Palle Petersen; Peter J Koudstaal; Yuchiao Chang; Beppie Hellemons Journal: JAMA Date: 2002-11-20 Impact factor: 56.272
Authors: Jeroen M L Hendriks; Rianne de Wit; Harry J G M Crijns; Hubertus J M Vrijhoef; Martin H Prins; Ron Pisters; Laurent A F G Pison; Yuri Blaauw; Robert G Tieleman Journal: Eur Heart J Date: 2012-03-27 Impact factor: 29.983
Authors: Daniel E Singer; Gregory W Albers; James E Dalen; Alan S Go; Jonathan L Halperin; Warren J Manning Journal: Chest Date: 2004-09 Impact factor: 9.410
Authors: Daniel E Singer; Gregory W Albers; James E Dalen; Margaret C Fang; Alan S Go; Jonathan L Halperin; Gregory Y H Lip; Warren J Manning Journal: Chest Date: 2008-06 Impact factor: 9.410
Authors: Andrew Frazer; James Rowland; Alison Mudge; Michael Barras; Jennifer Martin; Peter Donovan Journal: Eur J Clin Pharmacol Date: 2019-09-11 Impact factor: 2.953
Authors: Brigitte Fong Yeong Woo; Wilson Wai San Tam; Taiju Rangpa; Wei Fong Liau; Jennifer Nathania; Toon Wei Lim Journal: Int J Environ Res Public Health Date: 2022-04-07 Impact factor: 4.614
Authors: Jordy Mehawej; Jane Saczynski; Jerry H Gurwitz; Hawa O Abu; Benita A Bamgbade; Wei-Jia Wang; Tenes Paul; Katherine Trymbulak; Connor Saleeba; Zi-Yue Wang; Catarina I Kiefe; Robert J Goldberg; David D McManus Journal: J Geriatr Cardiol Date: 2020-08 Impact factor: 3.189